Screening for diabetes mellitus is strongly recommended among patients on antiretroviral therapy (ART). Both fasting and postprandial glucose values should be used to diagnose diabetes among HIV-infected cases. HbA1c may underestimate the degree of hyperglycemia and is not a good tool. Lipid abnormalities can be seen as early as 6 months of ART, so lipid profile should be done after 6 months of ART and then yearly.